                         SEQUENCE LISTING

<110>  SF17 Therapeutics, Inc.
 
<120>  COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE 
       NEURODEGENERATIVE DISEASES

<130>  5009/US:17:0003.02

<150>  US 62/720,138
<151>  2018-08-21

<160>  16    

<170>  PatentIn version 3.5

<210>  1
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain variable region

<400>  1

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ser Val Thr Gly Glu Pro Ile Thr Ser Gly 
            20                  25                  30          


Phe Trp Asp Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Phe Val 
        35                  40                  45              


Gly Met Ile Trp Gly Ala Asp Gly Asn Thr Asp Pro Asp Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Glu Asn Thr Lys Asn Ser Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Phe Tyr Asp Tyr Asp Val Phe Tyr Tyr Ala Met Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120         


<210>  2
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain variable region

<400>  2

Asp Ile Gln Leu Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Gly Asn Asn 
            20                  25                  30          


Lys Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Lys Ala Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln 
65                  70                  75                  80  


Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Asp Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  3
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain variable region

<400>  3

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Arg Ala Ser Gly Tyr Ala Ile Asn Gly Trp 
            20                  25                  30          


Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Tyr 
        35                  40                  45              


Pro Gly Ser Gly Gly Thr Ala Pro Asp Ser Val Lys Gly Arg Phe Thr 
    50                  55                  60                  


Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Val Leu Gln Met Asn Ser 
65                  70                  75                  80  


Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Tyr 
                85                  90                  95      


Ser Pro Thr Gly His Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Val Thr Val Ser Ser 
        115             


<210>  4
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain variable region

<400>  4

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gln Met Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Arg Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  5
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR of scFv3

<400>  5

Ser Val Thr Gly Glu Pro Ile Thr Ser Gly Phe Trp Asp 
1               5                   10              


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR of scFv3

<400>  6

Met Ile Trp Gly Ala Asp Gly Asn Tyr 
1               5                   


<210>  7
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR of scFv3

<400>  7

Asp Phe Tyr Asp Tyr Asp Val Phe Tyr Tyr Ala Met Asp Tyr 
1               5                   10                  


<210>  8
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR of scFv3

<400>  8

Arg Ala Ser Gln Ser Val Gly Asn Asn Lys Leu Ala 
1               5                   10          


<210>  9
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR of scFv3

<400>  9

Tyr Lys Ala Ser Asn Leu Ala Ser 
1               5               


<210>  10
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR of scFv3

<400>  10

Gln Gln His Asp Tyr Pro Tyr Thr 
1               5               


<210>  11
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR of scFv5

<400>  11

Arg Ala Ser Gly Tyr Ala Ile Asn Gly 
1               5                   


<210>  12
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR of scFv5

<400>  12

Asn Ile Tyr Pro Gly Ser Gly Gly Thr Ala 
1               5                   10  


<210>  13
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR of scFv5

<400>  13

Asp Arg Tyr Ser Pro Thr Gly His Tyr Tyr Gly Met Asp Val 
1               5                   10                  


<210>  14
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR of scFv5

<400>  14

Lys Ala Ser Gln Asp Ile Asn Ser Tyr Leu Asn 
1               5                   10      


<210>  15
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR of scFv5

<400>  15

Tyr Gln Met Ser Asn Leu Ala Ser 
1               5               


<210>  16
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR of scFv5

<400>  16

Gln Gln Phe Asn Arg Tyr Pro Leu Thr 
1               5                   


